121 results on '"Yun, Huifeng"'
Search Results
2. #2434 Literature review on the burden of herpes zoster in patients with kidney disease—a need for earlier prevention
3. Classifying Multimorbidity Using Drug Concepts via the Rx‐Risk Comorbidity Index: Methods & Comparative Cross‐sectional Study
4. Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
5. Identifying inpatient mortality in MarketScan claims data using machine learning
6. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
7. Reply
8. Geographic Variation in Disease Burden and Mismatch in Care of Patients With Rheumatoid Arthritis in the United States
9. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs – Analysis of a national claims database
10. Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
11. Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry
12. Inpatient Diagnosis of Delirium and Encephalopathy: Coding Trends in 2011–2018
13. Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry
14. Patient Valued Comparative Effectiveness of Corticosteroids versus Anti-TNF Alpha Therapy for Inflammatory Bowel Disease
15. ISPE‐Endorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVID‐19: Opportunities and Trade‐Offs
16. Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower® Registry
17. Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long‐Term Use of Glucocorticoids
18. The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases
19. Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry
20. Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis
21. Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
22. ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry
23. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
24. Evaluation of the Effect of Diabetes on Rheumatoid Arthritis–related Outcomes in an Electronic Health Record–based Rheumatology Registry
25. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis
26. Inpatient Diagnosis of Delirium and Encephalopathy: Coding Trends in 2011-2018
27. Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs
28. Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available
29. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
30. Factors associated with breast cancer screening behaviors in a sample of Jamaican women in 2013
31. Assessing Rheumatoid Arthritis Disease Activity With Patient‐Reported Outcomes Measurement Information System Measures Using Digital Technology
32. Human Papillomavirus Vaccination Schedule: Adherence Among Commercially Insured Adolescents and Young Adults in the United States, 2011–2017
33. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
34. Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat‐to‐Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology
35. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk
36. Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart
37. Capture of biologic and biosimilar dispensings in a consortium of U.S.‐based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims
38. Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States
39. Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?
40. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients
41. Risk for Herpes Zoster in Tofacitinib‐Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids
42. OP0082 TEMPORAL TRENDS OF BISPHOSPHONATE DISCONTINUATION AND FACTORS ASSOCIATED WITH ALENDRONATE DISCONTINUATION AND RESTART AT POPULATION LEVEL
43. Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient‐Reported Outcome Data Collection: A Qualitative Study
44. Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn’s Disease
45. Use of Medicare Claims Data for the Identification of Myocardial Infarction
46. Is Rheumatoid Arthritis a Cardiovascular Risk‐Equivalent to Diabetes Mellitus?
47. Reply
48. Socioeconomic Status and Race are both Independently associated with Increased Hospitalization Rate among Crohn’s Disease Patients
49. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease
50. Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.